TCGA-E2-A109-01A-11R-A10J-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 47
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.550
- G2M_CHECKPOINT+0.500
- MYC_TARGETS_V2+0.490
- MYC_TARGETS_V1+0.430
- INTERFERON_ALPHA_RESPONSE+0.340
- MITOTIC_SPINDLE+0.300
- UNFOLDED_PROTEIN_RESPONSE+0.250
- HEDGEHOG_SIGNALING+0.220
- DNA_REPAIR+0.160
- CHOLESTEROL_HOMEOSTASIS+0.140
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.360
- TNFA_SIGNALING_VIA_NFKB-0.360
- INFLAMMATORY_RESPONSE-0.300
- ALLOGRAFT_REJECTION-0.290
- KRAS_SIGNALING_UP-0.270
- NOTCH_SIGNALING-0.240
- P53_PATHWAY-0.230
- COAGULATION-0.220
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.220
- COMPLEMENT-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-34-5231-01A-21R-1820-07 | — | cohortSQ2 | 0.859 |
| 2 | TCGA-D8-A1XF-01A-11R-A14D-07 | — | B | 0.857 |
| 3 | TCGA-NC-A5HG-01A-11R-A26W-07 | — | cohortSQ1 | 0.856 |
| 4 | BS_B1C6GZ84 | Diffuse intrinsic pontine glioma | — | 0.850 |
| 5 | TCGA-BL-A3JM-01A-12R-A21D-07 | — | — | 0.837 |
| 6 | TCGA-BH-A18L-01A-32R-A12D-07 | — | B | 0.836 |
| 7 | TCGA-77-A5GF-01A-21R-A27Q-07 | — | cohortSQ2 | 0.832 |
| 8 | TCGA-34-5929-01A-11R-1820-07 | — | cohortSQ1 | 0.829 |
| 9 | 48e3eab5-b82e-4dbb-88d2-e5cfe295fa88 | — | — | 0.826 |
| 10 | SRR15030853 | — | — | 0.825 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.490 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.430 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.340 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.250 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.220 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.140 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.110 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.110 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.040 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.040 | Remibrutinib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.020 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.010 | Idelalisib | — uncovered |